REGRANEX by Smith and Nephew is clinical pharmacology 12. Approved for lower extremity diabetic neuropathic ulcers, beyond, used and 4 more indications. First approved in 1997.
Drug data last refreshed 3d ago · AI intelligence enriched 1mo ago
REGRANEX (becaplermin) is a topical gel formulation containing recombinant human platelet-derived growth factor (PDGF) approved in December 1997 for the treatment of lower extremity diabetic neuropathic ulcers. The product works by promoting chemotactic recruitment and proliferation of cells involved in wound repair and enhancing granulation tissue formation, mimicking the biological activity of endogenous PDGF. REGRANEX is indicated as an adjunctive therapy and is not a substitute for standard wound care practices including sharp debridement, pressure relief, and infection control. It represents a biologic approach to chronic wound management in the diabetic patient population.
Clinical Pharmacology 12.1 Mechanism of Action REGRANEX has biological activity similar to that of endogenous platelet-derived growth factor, which includes promoting the chemotactic recruitment and proliferation of cells involved in wound repair and enhancing the formation of granulation tissue.…
Worked on REGRANEX at Smith and Nephew? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moThree open positions are currently linked to REGRANEX, suggesting modest but active commercial operations. Roles likely include brand management, medical science liaisons focused on wound care specialists, and field sales representatives targeting wound centers, podiatry, and endocrinology practices. Key skills for REGRANEX team members include chronic wound pathophysiology knowledge, understanding of diabetic comorbidities, and ability to position a legacy biologic product against newer competitors in a competitive landscape. Success requires deep relationships with wound care specialists and comprehensive understanding of ulcer care protocols.